These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Alzheimer's disease and clinical trials. Paul D; Agrawal R; Singh S J Basic Clin Physiol Pharmacol; 2024 Jan; 35(1-2):31-44. PubMed ID: 38491747 [TBL] [Abstract][Full Text] [Related]
6. Current and novel therapeutic molecules and targets in Alzheimer's disease. Kumar A; Nisha CM; Silakari C; Sharma I; Anusha K; Gupta N; Nair P; Tripathi T; Kumar A J Formos Med Assoc; 2016 Jan; 115(1):3-10. PubMed ID: 26220908 [TBL] [Abstract][Full Text] [Related]
7. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials? Ehret MJ; Chamberlin KW Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885 [TBL] [Abstract][Full Text] [Related]
8. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. Matsunaga S; Kishi T; Iwata N PLoS One; 2015; 10(4):e0123289. PubMed ID: 25860130 [TBL] [Abstract][Full Text] [Related]
9. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576 [TBL] [Abstract][Full Text] [Related]